Omeros (OMER) Given a $24.00 Price Target at Maxim Group

Omeros (NASDAQ:OMER) received a $24.00 price objective from stock analysts at Maxim Group in a report released on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target points to a potential upside of 39.70% from the stock’s previous close.

OMER has been the topic of a number of other reports. HC Wainwright set a $30.00 price objective on shares of Omeros and gave the company a “buy” rating in a research note on Thursday, December 14th. Cowen downgraded shares of Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 price objective on shares of Omeros in a research note on Tuesday, November 28th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Omeros currently has an average rating of “Buy” and an average target price of $34.14.

Omeros (NASDAQ OMER) traded up $0.48 during midday trading on Monday, hitting $17.18. 1,263,465 shares of the stock were exchanged, compared to its average volume of 639,529. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99. Omeros has a 1 year low of $8.71 and a 1 year high of $27.09. The company has a market capitalization of $824.70, a P/E ratio of -13.32 and a beta of 3.56.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.18. The business had revenue of $21.66 million for the quarter, compared to the consensus estimate of $17.82 million. During the same quarter in the prior year, the business posted ($0.34) earnings per share. Omeros’s revenue for the quarter was up 91.9% on a year-over-year basis. equities research analysts expect that Omeros will post -0.98 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. First Interstate Bank acquired a new stake in Omeros in the third quarter valued at approximately $108,000. Legal & General Group Plc boosted its stake in Omeros by 7.8% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 751 shares in the last quarter. Hanseatic Management Services Inc. boosted its stake in Omeros by 10,919.6% in the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 10,592 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in Omeros in the third quarter valued at approximately $256,000. Finally, SG Americas Securities LLC boosted its stake in Omeros by 138.9% in the third quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 7,067 shares in the last quarter. Institutional investors own 49.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/omeros-omer-given-a-24-00-price-target-at-maxim-group.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply